Boston Therapeutics — Investor Presentation (April 2012)
15 slides from Boston Therapeutics's investor presentation, Apr 27, 2012
Slide 1: Investor Presentation April 2012 - Our Mission
Investor Presentation April 2012 Our Mission Boston Therapeutics, Inc. (BTI) mission is to research, develop and bring to market applied carbohydrate technologies that address unmet medical needs in the areas of diabetes and inflammatory diseases. Company: Boston Therapeutics, Inc. Sector: Pharmaceu
Slide 2: Forward-Looking Statement
Forward-Looking Statement Any statements about any possible future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements, which are subject to the safe
Slide 3: Investment Proposition
Investment Proposition OTC Consumer Product: SugarDown ®—BTI is in a unique position to capitalize on consumer demand for a non-systemic product that can help with blood glucose management after a meal. SugarDown® is already in direct sales channel in the U.S. and being sold through strategic partne
Slide 4: Market Approach
Market Approach Complex Carbohydrate FDA approved GRAS* Chemistry Glycemic Health SugarDown™ Consumer Brand OTC Initial Target Markets U.S. China Italy Phase I Trial Complete 6/2011 Product Available PAZ320 Pharmaceutical PAZ320 Clinical Trials Validation in clinical trials Dartmough-Hitchcock Medic
Slide 5: Case Study: Brand Distribution
Case Study Brand Distribution Pronova Biopharma $600 Million Market Cap REVENUE From active Pharmaceutical ingredient as food supplements Lovaza omega-3 acid ethyl esters Clinical Trials FDA Approval as OTC & Prescription Drugs gsk GlaxoKlineSmith Takeda AP Solvay Boston Therapeutics Business Develo
Slide 6: SugarDown -- Consumer Brand OTC
SugarDown™ -- Consumer Brand OTC The First Non-systemic Dietary Supplement to Moderate After-meal Blood Glucose Convenient Chewable Delivery Clinically Proven Safe Effective Ready for Market Mass Market Appeal Made in the U.S.A. Good Manufacturing Procedure (GMP) For Healthy, Overweight Or Pre-Diabe
Slide 7: Clinical Trials
Clinical Trials The University of Sydney SugarDown Research Group: University of Sydney Study: Phase I Determination of the postprandial glucose and insulin responses of white rice alone and white rice consumed with SUGARDOWN Status: Completed 2011 Findings: No serious adverse events, No withdrawals
Slide 8: How SugarDown Works -- Mechanism of Action
How SugarDown® Works -- Mechanism of Action Without SUGARDOWN® Enzymes Break down Complex Sugars into Simple Sugars Enzyme More Glucose Available for Absorption (Bad) With SUGARDOWN® Inhibition of Carbohydrate-cleaving Enzymes: Complex Sugars from Food Less (Good) Significant reduction in Post-meal
Slide 9: Product Pipeline
Product Pipeline Consumer Brand OTC Condition Market Status SUGARDOWN® Blood Glucose Control Phase I trial completed 6/11 Product available Claims accepted 2010 by FDA BTI-10 Lipid/Cholesterol Management In Development BTI-11 Intestinal Health BTI-12 Oral Probiotic Pharmaceutical PAZ320 Diabetes Pha
Slide 10: Market Size
Market Size U.S. Diabetic Facts Pre 2011 25.8 Million 79 Million 2030 30 Million Global Prevalence of Diabetes China 92 Million Europe 53 Million India 50 Million Mean National Expenditure per Diabetic $8,468 Age Group 20-79 -- Center for Disease Control 2011 Symbol: BTHE Confidential Property of Bo
Slide 11: What Consumers Have to Say...
What Consumers Have to Say... “I've been entertaining friends from France, and have been eating out more these past few days, up to 2x a day. With SUGARDOWN®, I've been getting totally normal blood sugar levels, 95 fasting, and under 130 post- meal. I took 2 tablets of SUGARDOWN® before eating a bow
Slide 12: Executive Team and Advisors
Executive Team and Advisors Our Executive Team can move products through FDA and into Consumer Markets David Platt, Ph.D. Chairman, Chief Executive Officer, Chief Financial Officer and Treasurer Dr. Platt is a world-renown expert in carbohydrate chemistry and has founded three publicly-traded compan
Slide 13: Executive Team and Advisors (cont'd)
Executive Team and Advisors (cont’d) Our Executive Team can move products through FDA and into Consumer Markets Carl L. Lueders, Audit Committee Chairman and Director Mr. Lueders has been a Director of the Company since September 2009, has a broad range of experience in finance, operations, short- a
Slide 14: Executive Team and Advisors (cont'd)
Executive Team and Advisors (cont’d) Yehuda Inbar, Vice President of IT/Media Mr. Inbar has been responsible for developing major online media projects for Microsoft, HP, Intel, AT&T and other major corporations. From 1997 to 2009, he was Information Solutions Architect and 3D Expert with Show & Tel
Slide 15: Boston Therapeutics, Inc. News
Boston Therapeutics, Inc. News April 18, 2012 Boston Therapeutics Receives First Purchase Order From Advance Pharmaceutical: SUGARDOWN® Sales in Hong Kong April 10, 2012 Boston Therapeutics PAZ320 Interim Clinical Trial Safety Results March 22, 2012 Boston Therapeutics Is Quoted as BTHE on the OTC B
Boston Therapeutics — Investor Presentation (April 2012) on 6ix